Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL
July 15th 2021Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Watch
CTCA In-Home Infusion Program Offers Patient-Centered Oncology Care
July 14th 2021Chevon Rariy, MD, discusses how the coronavirus disease 2019 pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.
Watch
Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL
July 8th 2021Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.
Watch
Follow-Up Shows Continued Efficacy in RCC With Pembrolizumab/Axitinib
July 7th 2021Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.
Watch
Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
July 1st 2021Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch